The Clinical Impact of Vascular Growth Factors and Endothelial Progenitor Cells in the Acute Coronary Syndrome

Wang Yongzhong,H. Johnsen,E. Jørgensen,J. Kastrup

DOI: https://doi.org/10.1080/14017430310006983

2003-01-01

Scandinavian Cardiovascular Journal

Abstract:Despite advances in drug therapy and percutaneous interventions, coronary heart disease remains a major cause of mortality and morbidity in industrialized countries. Morbidity in survivors of the acute coronary syndrome is related to myocardial remodeling and progressive heart failure. Therefore, treatment modalities that aim to reduce and repair the myocardial damage and improve blood supply to the myocardium in the ischemic heart are a challenge in clinical research. A new possible treatment modality is induction of vessel growth, angioneogenesis, to improve blood supply to the ischemic myocardium. A number of vascular growth factors that stimulate blood vessel formation are known and considered of clinical relevance (I). Clinical use of intramyocardial injection of genes encoding for growth factors to enhance or promote the development of collateral blood vessels in patients with angina have been and are presently being investigated in a placebo-controlled clinical trial (2,3). Also, recent studies in animals have demonstrated that circulating endothelial progenitor cells (EPCs) derived from the bone marrow can home to sites of f!eovascularization and differentiate into endothelial cells in situ creating myocardial vasculogenesis (3 , 4). Furthermore, it has been shown that mobilization of bone-marrow-derived EPCs seem to augment the neovascularization of ischemic tissue in an animal model, thus suggesting that drug-induced mobilization of EPCs might be of use in the clinical therapy of ischemic heart disease in humans (5). This review focuses on the two vascular growth factors VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor) and on bone-marrowderived EPCs in the development of new blood vessels in patients with the acute coronary syndrome. We focus on the natural acute and early changes of these angiogenic factors , in an attempt to reach a consensus, which might become a basis for new ideas on treatment regimes in the acute coronary syndrome. ANGIOGENIC FACTORS AND ENDOTHELIAL PROGENITOR CELLS